Steven Grunberg, M.D.

Professor of Medicine and Pharmacology

Research Program: Clinical Research
VCC Membership Level: Full Member

Contact Information

Division of Hematology/Oncology
Given Building E214
89 Beaumont Avenue
University of Vermont
Burlington, VT 05405

ph: (802) 656-5457
f: (802) 656-5493
Steven.Grunberg@uvm.edu

Biography

Dr. Grunberg received his M.D. degree from Cornell University Medical College in 1975. He trained in internal medicine at the University of California San Francisco Hospitals and in medical oncology at the Sidney Farber Cancer Institute. He served on the faculty of the University of Southern California from 1981 until 1993, when he joined the faculty of the UVM College of Medicine. Dr. Grunberg serves on the Vermont Cancer Center Protocol Review Committee and Clinical Research Oversight Committee. He is a former Chair of NCI Initial Review Group Subcommittee G (Education). He is presently the Editor of the Proceedings of the American Society of Clinical Oncology, a member of the Board of Directors of the Northern New England Clinical Oncology Society, and Treasurer of the Multinational Association of Supportive Care in Cancer.

Research

Dr. Grunberg's research interests are in developmental chemotherapy and early clinical trials of new anti-cancer agents. His work has spanned early clinical trials of cytotoxics, biologics, antiemetics, and differentiating agents. Present efforts include development of new and more effective treatment strategies for lung cancer, and head and neck cancer. He also continues a major effort in supportive care and symptom management, including pharmacologic interventions, evaluation of patient and healthcare professional perceptions, and pharmacoeconomic analysis.

Recent Publications

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlman GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.

Witherby SM, Butnor KJ, Grunberg SM. Malignant mesothelioma following thoracic radiotehrapy for lung cancer. Lung Cancer 2007;57:410-3.

Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9.

Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-33

Grunberg SM, Dugan MC, Greenblatt MS, Ospina DJ, Valentine JW. Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer. Cancer Invest 2005;23:392-8

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30

Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005 Feb 13(2), 112-6. 

Grunberg SM. New directions in supportive care. Support Care Cancer 2005 Mar 13(3), 135-7. 

Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005 Feb 13(2), 80-4. 

Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005 Feb 13(2), 85-96. 

Gillani AA, Grunberg SM. Aerorespiratory tract cancer in older patients. Semin Oncol 2004 Apr 31(2), 220-33.

Grunberg SM. New developments in the management of chemotherapy-induced emesis: do they impact on existing guidelines? Oncology (Huntingt) 2004 Sep 18(10 Suppl 6), 15-9. 

Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004 May 15 100(10), 2261-8. 

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003 May 1; 97(9):2290-300.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003 Dec 1 98(11), 2473-82. 

Grunberg SM, Cefalu WT. The integral role of clinical research in clinical care. N Engl J Med 2003 Apr 3 348(14), 1386-8. 

Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003 Dec 4(12), 2297-303. 

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003 Nov 15 21(22), 4112-9. 

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 2003 Jul 39(10), 1395-401. 

Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. European Journal of Cancer 2003 Jul ; 39(10):1395-401.

Other Key Publications

Grunberg SM, Sofferman R, Roland T, Shubel S. Hemialopecia due to Regional Chemotherapy. J Clin Oncol 1999 17:430-431.

Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1 Receptor Antagonist. N Engl J Med 1999 340:190-195.

Grunberg SM, Spears CP, Natale R, Zaretsky S, Ashikaga T. Phase I Evaluation of High-Dose Edatrexate (EDX) with Leucovorin (LV) Rescue. Proc ASCO. 1994 13: 146.

Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, Moran RG. Phase I Study of 5, 10-Dideazatetrahydrofolate: A Folate Antimetabolite Inhibitory to De Novo Purine Synthesis. J Natl Can Inst. 1993 85: 1145-1159.

Grunberg SM, Ehler E, Francis RB Jr., Mitchell MS. Phase I Trial of a 5-Day Course of Carbetimer. Invest New Drugs. 1990 8: S41-S49.

Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose Ranging Phase I Study of the Serotonin Antagonist GR38032F for Prevention of Cisplatin Induced Nausea and Vomiting. J Clin Oncol. 1989 7: 1137-1141.

Grunberg SM, Kempf RA, Venturi CL, Mitchell MS. Phase I Study of Recombinant Interferon Beta by Four Hour Infusion. Cancer Res. 1987 47: 1174-1178.